Transcriptional Regulation of Metastatic [Id]entity by KLF17 by Iwanicki, Marcin & Brugge, Joan S.
 
Transcriptional Regulation of Metastatic [Id]entity by KLF17
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Iwanicki, Marcin P., and Joan S. Brugge. 2009. Transcriptional
regulation of metastatic [Id]entity by KLF17. Genome Biology
10(11): 244.
Published Version doi:10.1186/gb-2009-10-11-244
Accessed February 19, 2015 8:44:23 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:5089314
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAhttp://genomebiology.com/2009/10/11/244  Iwanicki and Brugge: Genome Biology 2009, 10:244
Abstract
A novel in vivo screening approach has identified KLF17 as a 
key metastasis suppressor gene that acts through regulation of 
Id1 transcription factor-dependent induction of the epithelial-to-
mesenchymal transition.
The development and growth of a malignant tumor relies 
on molecular changes that affect the function of cellular 
proto-oncogenes  and  tumor  suppressors  [1].  Certain 
alterations are required constitutively during tumor initia-
tion and progression, whereas others are more speci  fi  cally 
associated with aspects of tumor metastasis - the spread of 
malignant cells to secondary tissues. Metastasis suppres-
sors are proteins that specifically repress events associated 
with  metastasis  without  affecting  primary  tumor  growth 
[2]. In a recent paper in Nature Cell Biology, Huang and 
colleagues  (Gumireddy  et  al.  [3])  describe  experiments 
that identify a new metastasis suppressor, KLF17.
The course of metastasis
Progression  towards  metastatic  disease  involves  a  distinct 
sequence of events. Tumor cells attract endothelial cells to 
promote  angiogenesis;  dissociate  from  the  primary  tumor 
mass  and  migrate  towards  endothelial  cells;  intravasate 
through endothelial cells and the surrounding matrix; enter 
the  intra-tumoral  vasculature;  exit  the  vasculature  at  the 
secondary  sites;  infiltrate  the  new  environment;  and 
establish growing malignant colonies within a new organ [4]. 
These events are likely to be driven in large part by changes 
in transcriptional programs that affect expression of genes 
required  for  these  processes  (for  example,  genes  that 
promote angiogenesis, cell adhesion and matrix proteo  lysis). 
These transcriptional changes are mediated by alterations in 
the  tumor  microenvironment  [5]  as  well  as  by  genetic 
alterations in proto-oncogenes and tumor suppressors [6]. 
For  example,  many  reports  have  shown  that  oncogenic 
mutations in H-Ras or loss of p53 tumor suppressor function 
induce  trans  criptional  programs  that  promote  metastasis 
through altera  tions in the expression of genes required for 
the invasion of cancer cells into the surrounding tissues [4,7-
10]. Transcrip  tion factors that promote the loss of epithelial 
characteristics, such as (cell-to-cell) adhesion, have also been 
proposed to play a key role in the initiation of metastasis.
The  epithelial-to-mesenchymal  transition  (EMT)  was 
initially  described  as  a  fundamental  process  that  drives 
morphogenetic tissue movements in animal embryos [11]. 
Increasing evidence supports the hypothesis that epithelial 
tumors adopt EMT-like characteristics during the invasion 
of proximal tissues [12,13]. EMT involves the loss of apico-
basal  epithelial  cell  polarity  and  the  development  of  a 
migratory  polarity  (leading  edge  and  trailing  edge)  that 
promotes migration [14].The molecular hallmarks of EMT 
include  the  increased  expression  of  transcription  factors 
that  contribute  to  the  loss  of  cell  adhesion  through  the 
downregulation of the cell adhesion molecule E-cadherin 
and increased proteolysis of the surrounding extracellular 
matrix  as  a  result  of  the  elevated  expression  of  matrix 
metalloproteinases [14]. Cells that have undergone EMT in 
culture show an increased capability for invasive behavior 
in vitro and in vivo [12].
Genome-wide screen for metastasis 
suppressors
Gumireddy et al. [3] used a genome-wide screen to identify 
genes  that  induce  metastasis  when  their  expression  is 
attenuated.  Non-invasive  mouse  mammary  tumor  cells 
were transduced with a genome-wide short hairpin RNA 
(shRNA) library and implanted into mouse mammary fat 
pads.  Lung  metastases  that  developed  in  these  animals 
were then analyzed by PCR for the most abundant shRNA 
transcripts, one of which was found to target expression of 
Krüppel-like transcriptional factor 17 (KLF17). Gumireddy 
et al. [3] then found that shRNA-mediated attenuation of 
KLF17  expression  in  the  MCF-7  line  of  human  non-
metastatic breast cancer cells promoted lung metastases in 
mice  into  which  the  treated  cells  were  introduced.  In 
addition, the overexpression of KLF17 in highly metastatic 
4T1  mouse  breast  cancer  epithelial  cells  decreased  the 
number of lung metastases in mice compared to control 
cells.  These  experiments  provide  strong  evidence  that 
KLF17 is a new metastasis suppressor gene.
KLF17 belongs to the Sp (small protein)/KLF zinc-finger 
protein  family.  Other  members  of  this  family  have  been 
shown to regulate cell invasion in vitro [15]. For example, 
ectopic  expression  of  KLF4  and/or  KLF5  blocked  the 
invasive behavior of esophageal cancer cells in vitro [15]. 
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However, the exact mechanisms by which these proteins 
achieve  their  suppressive  effect  was  not  understood. 
Gumireddy  et  al.  [3]  employed  microarray  analysis  of 
mRNAs in cells subjected to loss or gain of KLF17 expres-
sion to provide insights into the mechanisms by which KLF 
family members suppress cell invasiveness and metastasis. 
They show in particular that shRNA-mediated attenuation 
of  KLF17  levels  in  non-metastatic  cells  induces  an  EMT 
‘signature’ of gene expression and increased expression of 
inhibitor of differentiation-1 (Id1), which is known to be a 
negative  regulator  of  basic  helix-loop-helix  family  trans-
cription  factors  and  to  be  involved  in  promot  ing  EMT. 
Conver  sely, overexpression of KLF17 suppressed Id1 expres-
sion. The authors further show that KLF17 sup  presses Id1 
expression directly by binding to its promoter region. Id1 
and  KLF17  have  opposite  effects  on  a  tumor’s  ability  to 
metastasize. Primary tumor samples with high Id1 and low 
KLF17  expression  were  highly  metastatic,  where  as  those 
with higher expression of KLF17 and lower levels of Id1 
were less metastatic. Taken together, these data support 
the conclusion that Id1 plays a critical role in the regulation 
of metastasis by KFL17.
Id1 and human cancer
ID1 is overexpressed in various human cancers, including 
endometrial, ovarian, prostate and breast cancers [16], and 
had  previously  been  shown  to  promote  invasion  and 
metastasis [10]. In tubular epithelial cells, ID1 was shown to 
be required for transforming growth factor-β-mediated loss 
of  E-cadherin  expression  (a  molecular  hallmark  of  EMT) 
[17].  ID1-mediated  downregulation  of  E-cadherin  occurs 
through the direct binding of Id1 protein to the trans  cription 
factor HEB (HELA E-box binding factor), which prevents 
HEB  from  accessing  the  E-cadherin  promoter  [17]. 
Interestingly,  Gumireddy  et  al.  [3]  show  that  the  loss  of 
KLF17 function in the NMuMg mouse mammary epithelial 
cell line transformed by the oncogene V12H-Ras enhances its 
capacity to produce lung metastases and drives metastasis to 
several  other  organs.  Given  that  V12H-Ras  induces  EMT 
[18-20], these results suggest that processes in addition to 
EMT contribute to the promotion of metastasis by Id1. For 
example, Id1-induced metastasis could also involve tumor 
vascularization,  as  Id1  promotes  production  of  vascular 
endothelial  growth  factor  (VEGF)  in  prostate  cancer  cells 
[21]. Taken together, these studies suggest a model in which 
loss of KFL17 leads to induction of ID1, which could promote 
primary  tumor  vascularization  via  VEGF  production  and 
initiate  invasion  through  EMT-associated  processes, 
including  loss  of  E-cadherin  adhesions  and  increased 
activation of matrix metalloproteinases.
One important question raised by the work of Gumireddy 
et  al.  [3]  is  whether  the  regulation  of  KLF17  is  entirely 
transcriptional  or  if  its  activity  is  also  regulated  post-
translationally,  and  what  upstream  factors  control  gene 
expression or protein activity. The transcriptional activity 
of  Sp1/KLF  family  members  has  been  shown  to  be 
regulated post-translationally by phosphorylation [8,22]. A 
search for phosphorylation-site motifs using Scansite [23] 
predicts a high-stringency target site for phosphorylation 
by protein kinase C-ε (PKCε) within the amino-terminal 
region of KLF17. Given that the activity of some Sp1/KLF 
family members is known to be regulated by PKC isoforms 
[8,24-26],  it  is  plausible  that  the  ability  of  KLF17  to 
suppress  ID1  transcription  could  be  either  positively  or 
negatively tuned by some PKCs (Figure 1). However, future 
experiments addressing the mechanisms of KLF17 regu  la-
tion will be needed to fill this gap in our under  standing of 
metastatic progression.
The  findings  of  Gumireddy  et  al.  [3]  highlight  the 
feasibility and the value of in vivo loss-of-function screens. 
As the authors point out, these screens should be carried 
out  in  models  other  than  breast  cancer,  as  distinct 
transcription factors might play a role in the regulation of 
invasion and metastasis in different cancer types.
Figure 1
Regulation of ID1 expression by KLF17. ID1 transcription is suppressed by KLF17 binding to the ID1 promoter. Loss of expression of KLF17 
by transcriptional suppression or inactivation by post-translational modification (possibly by phosphorylation or dephosphorylation) leads to 
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